Location History:
- Arslev, DK (2015)
- Årslev, DK (2021)
Company Filing History:
1 out of 3 
1 out of 38 
1 out of 4 Years Active: 2015-2021
Title: Innovations of Thorleif Møller in the Field of Myotonic Dystrophy Treatment
Introduction
Thorleif Møller is an accomplished inventor based in Årslev, Denmark. He has made significant contributions to the field of medical research, particularly in the treatment of myotonic dystrophy type 1. His innovative approach focuses on the modulation of microRNAs, which play a crucial role in the disease's pathology.
Latest Patents
Thorleif Møller holds a patent titled "Modulation of microRNAs against myotonic dystrophy type 1 and antagonists of microRNAs therefor." This invention provides a method for using inhibitors of microRNAs that repress the MBNL1 and/or MBNL2 genes. The patent outlines the potential for these inhibitors to be developed into medicinal products aimed at treating myotonic dystrophy type 1. By inhibiting specific microRNAs, such as miR-23b-3p and miR-218-5p, the invention aims to increase the levels of the corresponding proteins, thereby alleviating symptoms associated with the disease.
Career Highlights
Throughout his career, Thorleif Møller has worked with notable institutions, including Universitat De Valencia and Aum Lifetech, Inc. His research has focused on the intersection of molecular biology and therapeutic development, leading to advancements in the treatment of genetic disorders.
Collaborations
Thorleif Møller has collaborated with esteemed colleagues, including Rubén D Artero Allepuz and María Beatriz Llamusí Troisi. These partnerships have contributed to the depth and impact of his research in the field.
Conclusion
Thorleif Møller's innovative work in the modulation of microRNAs represents a significant advancement in the treatment of myotonic dystrophy type 1. His contributions continue to pave the way for new therapeutic strategies in addressing this challenging condition.